dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Posição atual:
>
> This Story


Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Health IT Homepage

Want to reduce readmissions? Let’s start with keeping patients healthier Insights from Robin Hill, chief clinical officer at Vivify Health

Decision support software could reduce scans by 6 percent: MIT researchers Prevent overuse of powerful and costly imaging exams

CMS to add more telehealth benefits to Medicare Advantage plans Aiming for greater flexibility, lower costs

Fredrik Palm ContextVision appoints new CEO

Trice Imaging connects imaging devices of large chain healthcare provider Aleris Patients and physicians can view images on laptops, cell phones

Three recommendations to better understand HIPAA compliance Approximately 70 percent of organizations are not HIPAA compliant

Researchers orchestrate malware attack to expose imaging vulnerabilities Deceived radiologists and AI algorithms into misdiagnoses

How hyper-targeting patient communications can improve medication adherence Providing specific messages can make a world of difference

Sound Imaging launches MR patient motion and detection system, SAMM MD Reduces repeat scans, prevents interruption to workflow

Where are your patients going? Keeping patients from switching to a new provider is good business and good medicine

Ibex's Second Read System

First AI pathology diagnostic system up and running in clinical setting

por John R. Fischer , Staff Reporter
The first AI-based pathology diagnostic system is up and running in a live clinical setting to assist in the confirmation of prostate cancer.

The Institute of Pathology at Maccabi Healthcare Services in Israel has deployed Ibex Medical Analytics’ Second Read (SR) System to identify various cell types and features within whole slide images of prostate core needle biopsies (PCNBs), including grading cancerous glands and other clinically significant features. Its use follows a pilot period in which it identified isolated major errors in retrospective PCNBs that were previously diagnosed as benign by pathologists.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



“Prostate cancer diagnosis is labor intensive,” Joseph Mossel, co-founder and CEO of Ibex, the strategic partner of Maccabi, told HCB News. “It requires reviewing a large number of biopsy slides with potential for a human pathologist to miss relatively small cancer foci. Furthermore, there is potential for more mundane human error such as missing a slide within a case, typing errors and so forth. These risks have become more pronounced in recent years with an ever-increasing workload and a global shortage of pathologists.”

The SR system analyzes the entire case and alerts users to discrepancies found with the original diagnosis.

Following its deployment, the solution utilized AI and machine learning techniques to identify a suspicious PCNB that was diagnosed earlier in the day as benign by a pathologist at the institute, which handles approximately 700 PCNBs out of 160,000 histology accessions annually.

Staff re-examined the PCNB and confirmed the presence of low-grade prostate cancer, demonstrating the higher efficiency and accuracy of the platform.

System training is derived from thousands of image samples of hundreds of PCNBs in multiple institutes. Digital images used for this initiative were produced by The Maccabi Pathology Institute’s Philips IntelliSite Pathology solution.

Training is currently limited to the prostate with the potential to teach the system how to diagnose other forms of cancer provided a large enough training set is available. This, however, could be a challenge for very rare types of cancer.

Mossel says, however, that the deployment of the system provides faster diagnoses and better management of population health in a cost-effective manner.

“The system allows for better management and improvement of population health while controlling for costs,” he said. “The deployment of AI-based tools for cancer diagnostics in pathology leads to faster diagnosis and associated treatment, increased efficiency, and increased accuracy.”

Ibex plans to expand the number of cancer types and clinical use cases the solution can address as part of its focus to make the SR system a commercially available product.

Availability of the platform is currently limited.

Health IT Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente a Sua Perceção da Marca
Leilões + Vendas Privadas
Comece
O mais melhor preço
Comprar Equipamento/Peças
Encontre
O preço o mais baixo
Notícia diária
Leia
A notícia a mais atrasada
Diretório
Browse tudo
DOTmed Usuários
Ética no DOTmed
Veja o nosso
Programa das éticas
O ouro parte o programa do vendedor
Receba PH
Pedidos
Programa do negociante do serviço do ouro
Receba RFP/PS
Pedidos
Fornecedores de Healthcare
Veja tudo
Ferramentas de HCP
Trabalhos/Treinamento
Achado/suficiência
Um trabalho
Parts Hunter +EasyPay
Comece as peças
Citações
Certificado recentemente
Vista recentemente
Usuários certificados
Recentemente Rated
Vista recentemente
Usuários certificados
Central Rental
Equipamento do aluguel
Para menos
Vender Equipamentos/Peças
Comece
A maioria de dinheiro
Preste serviços de manutenção ao Forum dos técnicos
Ajuda do achado
E conselho
Simples RFP
Comece o equipamento
Citações
Mostra de comércio virtual
Serviço do achado
Para o equipamento
O acesso e o uso deste local são sujeitos aos termos e às condições do nosso OBSERVAÇÃO LEGAL & OBSERVAÇÃO DA PRIVACIDADE
Propriedade de e proprietário DOTmeda .com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
TODOS OS DIREITOS RESERVADOS